RAQUEL
RIVERA DÍAZ
Profesora asociada de Ciencias de la Salud
Ignacio
García Doval
Publicacions en què col·labora amb Ignacio García Doval (31)
2024
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
2023
-
Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
BMJ open, Vol. 13, Núm. 7, pp. e075197
-
Erythrodermic Psoriasis Has Become Less Frequent: Results From the Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T366-T369
2022
-
Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry
British Journal of Dermatology
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117
-
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population
Journal of the European Academy of Dermatology and Venereology
2021
-
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741
2019
-
Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study
Journal of Dermatological Treatment, Vol. 30, Núm. 5, pp. 461-465
-
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population
British Journal of Dermatology
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016
Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 617-623
2017
-
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1700-1708
-
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028
-
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321
-
Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts
British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649